AI play Atomwise to build internal pipeline with $123M series B

After building and validating its AI-driven small molecule discovery platform through partnerships, Atomwise has raised a $123 million series B round that will enable the company to begin building its own pipeline. 

Since its 2012 launch, Atomwise Inc. has used its AtomNet platform to deliver drug candidates to biopharma partners including Pfizer Inc. (NYSE:PFE) and Eli Lilly and Co. (NYSE:LLY), and has moved other platform-generated programs forward via a series of JVs. AtomNet uses structural information to predict binding between molecular targets and small molecules by processing millions of data points regarding successful and unsuccessful ligand-binding interactions (see “Testing Intelligence”; “Atomwise’s JV Spree”).  ...